Phase 3 Trial to Evaluate the Efficacy and Safety of YYC506.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 554 participants.
Also called NCT04858308
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 554 participants
- Sponsor
- Yooyoung Pharmaceutical Co., Ltd.
- Registry
-
NCT04858308
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Unknown status
Technical summary
Registry record NCT04858308. Randomized; quadruple masking; primary purpose treatment. Start 2021-01-29 (actual); primary completion 2021-05-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase 3 Trial to Evaluate the Efficacy and Safety of YYC506.
- Acronym
- Atorf-YOOrct
- Condition
- Dyslipidemias
- Intervention (Drug)
- YYC506
- Intervention (Drug)
- Control
- Intervention (Drug)
- YYC506 Placebo
- Intervention (Drug)
- Control Placebo
- Lead sponsor
- Yooyoung Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct04858308- Content hash
09fa0ec813401058d962739ce919307f15c6daae66baa86ba8e8bc1440a4bdcf